Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

FORGOTTEN HISTORY: Benzinga s top ratings upgrades downgrades for may 31 2022 - The Untold Story

Upgrades

Guggenheim upgraded the previous rating for Novo Nordisk A/S (NYSE:NVO) from Neutral to Buy. Novo Nordisk earned $0.94 in the first quarter, compared to $0.88 in the year-ago quarter. The stock has a 52-week-high of $122.16 and a 52-week-low of $78.71. At the end of the last trading period, Novo Nordisk closed at $107.74.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.